Brand Intelligence Graph
Company Overview
About Turn Biotechnologies
Turn Biotechnologies is a longevity company using modified mRNA cocktails to transiently reprogram aged cells back toward a youthful epigenetic state — without permanently altering DNA sequences. The company has raised $29 million in Series A financing and acquired ARMMs (Arrestin Domain-Containing Protein 1 Mediated Microvesicle) technology in March 2025 to significantly upgrade the delivery capability of its mRNA reprogramming platform.
Business Model & Competitive Advantage
The mRNA reprogramming approach is designed to be reversible and transient: unlike CRISPR or viral gene therapies that make permanent changes to DNA, Turn's mRNA molecules naturally degrade after delivering their cellular reprogramming instructions. This potentially safer profile addresses one of the primary clinical concerns with epigenetic reprogramming approaches — the risk that partial reprogramming might induce inappropriate cell state changes that persist.
Competitive Landscape 2025–2026
Turn's dermatology beachhead — applying mRNA reprogramming to aged skin cells to demonstrate in vivo rejuvenation before advancing to systemic conditions — is a clinically accessible first proof point. Skin is directly observable, has established outcome metrics, and allows safety assessment without the systemic monitoring required for internal tissue reprogramming. The ARMMs acquisition significantly upgrades the mRNA delivery system, improving cellular uptake and reducing immune response to the delivery vehicle.
Key Differentiators
Emerging Innovator
Turn Biotechnologies is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Turn Biotechnologies with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Turn Biotechnologies? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Turn Biotechnologies Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Turn Biotechnologies vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →